Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 3-Day, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Effect of Armodafinil Treatment (50 and 150 mg/Day) in Healthy Subjects With Excessive Sleepiness Associated With Jet Lag Disorder.

Trial Profile

A 3-Day, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Effect of Armodafinil Treatment (50 and 150 mg/Day) in Healthy Subjects With Excessive Sleepiness Associated With Jet Lag Disorder.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 22 Jul 2013

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Armodafinil (Primary)
  • Indications Jet lag
  • Focus Therapeutic Use
  • Sponsors Cephalon
  • Most Recent Events

    • 27 Dec 2010 According to a Cephalon media release, a second Complete Response Letter from the US FDA has been received for the sNDA based on this trial. Cephalon believes that this application will not be approved, and is no longer pursuing this indication.
    • 01 Jul 2010 Results have been published in the Mayo Clinic Proceedings.
    • 24 Sep 2009 Armodafinil has been granted priority review. The decision on approval is expected by 29 Dec, 2009, according to a Cephalon media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top